| Ying Wang,Ruifan Xie,Hongquan Niu,Ting Lei. IL-13Ra2- and glioma stem cell-pulsed dendritic cells induce glioma cell death in vitro. Oncol Transl Med, 2016, 2: 210-215. |
| IL-13Ra2- and glioma stem cell-pulsed dendritic cells induce glioma cell death in vitro |
| Received:July 11, 2016 Revised:July 11, 2016 |
| View Full Text View/Add Comment Download reader |
| KeyWord:dendritic cell; brain tumor stem cell; IL-13Ra2; glioma |
| Author Name | Affiliation | E-mail | | Ying Wang | Department of Neurosurgery, Tumor Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, P. R. China | 654614745@qq.com | | Ruifan Xie | Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China | 654614745@qq.com | | Hongquan Niu | Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China | 654614745@qq.com | | Ting Lei | Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P. R. China | hufeng268@qq.com |
|
| Hits: 6550 |
| Download times: 7660 |
| Abstract: |
| Objective Gliomas are the most common malignant tumors in the central nervous system. Despite multiple therapies including surgery, chemotherapy, and radiotherapy, the prognosis of patients remains poor.
Immunotherapy is an alternative method of treating glioma, and the use of dendritic cell vaccines is one of
the promising treatment options. However, there is no specific tumor cell antigen that can trigger dendritic
cells (DCs). IL-13Ra2 is a specific antigen expressed in glioma cells; in the current study, we have attempted to explore whether IL-13Ra2 could be the antigen that triggers DCs and to envisage its application
as potential therapy for glioma.
Methods The expression of IL-13Ra2 was detected in U251 glioma cell lines and primary glioma tissues
using different methods. DCs from human blood were isolated and pulsed with recombinant IL-13Ra2, following which the cytotoxicity of these DCs on glioma cells was detected and analyzed.
Results About 55.9% human glioma tissue cells expressed IL-13Ra2, while normal brain tissue cells did
not show any expression. DC vaccines loaded with IL-13Ra2, glioma cell antigen, and brain tumor stem cell
(BTSC) antigen could significantly stimulate the proliferation of T lymphocytes and induce cell death in the
glioma tissue. Compared to other groups, DC vaccines loaded with BTSC antigen showed the strongest
ability to activate cytotoxic T lymphocytes (CTLs), while the glioma cell antigen group showed no significant
difference.
Conclusion IL-13Ra2, which is expressed in gliomas and by glioma stem cells, as well as IL-13Ra2
could prove to be potential antigens for DC vaccine-based immunotherapy.
|
| Close |
|
|
|